Combination of radiation therapy and interferon alpha-2b in patients with advanced cervical carcinoma: a pilot study

Verástegui-Avilés, Emma; Mohar, Alejandro; Mota, A.; Salido-Guadarrama, Iván; Garza-Salazar, Jaime de la

doi:10.1046/j.1525-1438.1999.99053.x

Cited by 15 publications

(7 citation statements)

References 29 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Park ( 24 ) treated 15 patients with advanced cervical cancer with interferon α‐2a, 13‐ cis ‐retinoic acid, and radiation therapy, obtaining a 33% complete response rate, compared to 17% complete responses in a chemoradiation historical control group, concluding that the bioradiation combination is active and tolerable in the treatment of these patients. Verastegui ( 25 ) treated 17 patients with radiation therapy and interferon α‐2b, obtaining 11 (64%) complete responses in patients with stages III and IV with long‐term survival observed in four patients (24%). Remarkable in this study is the high incidence of proctitis reported in 13 of 17 patients with three (23%) of them requiring a colostomy, compared to their historical incidence of 11%.…”

Section: Discussionmentioning

confidence: 99%

Phase III randomized pilot study comparing interferon alpha- 2b in combination with radiation therapy versus radiation therapy alone in patients with stage III-B carcinoma of the cervix

Yazigi

Aliste

Torres

et al. 2003

Int J Gynecol Cancer

View full text Add to dashboard Cite

This randomized pilot study was designed to determine whether the addition of interferon alpha-2b to standard radiation therapy offered an advantage in loco-regional control and survival over radiation therapy alone in a homogeneous group of patients with stage IIIB carcinoma of the cervix. Thirty-six patients were treated with a combination of interferon alpha-2b plus radiation therapy, and 38 patients were treated with radiation therapy alone. Patients with evidence of ureteral obstruction were excluded from the study. Evaluation of loco-regional response was determined by pelvic examination, cervical cytology, biopsies and CT scans when indicated. Survival time was measured from initiation of treatment to date of death or last follow-up. Patient characteristics were comparable between both study arms. The objective complete response rate was 67% in the combined therapy group and 55% in the radiation alone group (P = 0.454). With a median follow-up of 17 months for all patients and 31 months for live patients, 50% of the combined group survived vs. 39.5% of the radiation alone group (P = 0.424). We conclude that the addition of interferon alpha-2b to standard radiation therapy did not significantly improve loco-regional response or survival, although such a trend was noted. We encourage the design of a larger randomized study with sufficient power to detect meaningful differences to prove whether the tendency observed in the present investigation holds any promise to improve the outcome of these patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Phase III randomized pilot study comparing interferon alpha- 2b in combination with radiation therapy versus radiation therapy alone in patients with stage III-B carcinoma of the cervix

Yazigi

Aliste

Torres

et al. 2003

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

“…Park (24) treated 15 patients with advanced cervical cancer with interferon a-2a, 13-cis-retinoic acid, and radiation therapy, obtaining a 33% complete response rate, compared to 17% complete responses in a chemoradiation historical control group, concluding that the bioradiation combination is active and tolerable in the treatment of these Interferon a-2b and radiation therapy in cervical carcinoma 167 patients. Verastegui (25) treated 17 patients with radiation therapy and interferon a-2b, obtaining 11 (64%) complete responses in patients with stages III and IV with long-term survival observed in four patients (24%). Remarkable in this study is the high incidence of proctitis reported in 13 of 17 patients with three (23%) of them requiring a colostomy, compared to their historical incidence of 11%.…”

Section: Discussionmentioning

confidence: 99%

Phase III randomized pilot study comparing interferon α- 2b in combination with radiation therapy versus radiation therapy alone in patients with stage III-B carcinoma of the cervix

Yazigi¹,

Aliste²,

Torres³

et al. 2003

Int J Gynecol Cancer

View full text Add to dashboard Cite

This randomized pilot study was designed to determine whether the addition of interferon α-2b to standard radiation therapy offered an advantage in loco-regional control and survival over radiation therapy alone in a homogeneous group of patients with stage IIIB carcinoma of the cervix. Thirty-six patients were treated with a combination of interferon α-2b plus radiation therapy, and 38 patients were treated with radiation therapy alone. Patients with evidence of ureteral obstruction were excluded from the study. Evaluation of loco-regional response was determined by pelvic examination, cervical cytology, biopsies and CT scans when indicated. Survival time was measured from initiation of treatment to date of death or last follow-up. Patient characteristics were comparable between both study arms. The objective complete response rate was 67% in the combined therapy group and 55% in the radiation alone group (P = 0.454). With a median follow-up of 17 months for all patients and 31 months for live patients, 50% of the combined group survived vs. 39.5% of the radiation alone group (P = 0.424). We conclude that the addition of interferon α-2b to standard radiation therapy did not significantly improve loco-regional response or survival, although such a trend was noted. We encourage the design of a larger randomized study with sufficient power to detect meaningful differences to prove whether the tendency observed in the present investigation holds any promise to improve the outcome of these patients.

show abstract

“…63 As a result, further variations have been explored such as the use of proton beams as opposed to electromagnetic radiation. Experience with doxorubicin and interferon with cervical cancer has shown rates of proctitis up to 75 percent, 65 whereas bleomycin is one exception, with no worsening of rectal outcomes. 56 In a small study of patients in Japan, 2 of 15 (13 percent) patients developed only proctitis, but use of proton beams is limited at present by expense and access to machinery.…”

Section: Treatment Factorsmentioning

confidence: 99%

Management of Late Complications of Pelvic Radiation in the Rectum and Anus

Johnston

Robertson

Frizelle

2003

Diseases of the Colon &Amp; Rectum

View full text Add to dashboard Cite

Many of these symptoms are self-limiting, and mucosal complications may often be treated by nonsurgical methods such as topical formalin application, endoscopic argon plasma coagulation, and hyperbaric oxygen therapy. Conservative measures have not been shown to be of benefit if symptoms persist. Structural abnormalities and septic complications are likely to require surgery. Modern techniques in the delivery of radiotherapy help minimize the likelihood of rectal complications.

show abstract

Combination of radiation therapy and interferon alpha-2b in patients with advanced cervical carcinoma: a pilot study

Cited by 15 publications

References 29 publications

Phase III randomized pilot study comparing interferon alpha- 2b in combination with radiation therapy versus radiation therapy alone in patients with stage III-B carcinoma of the cervix

Phase III randomized pilot study comparing interferon alpha- 2b in combination with radiation therapy versus radiation therapy alone in patients with stage III-B carcinoma of the cervix

Phase III randomized pilot study comparing interferon α- 2b in combination with radiation therapy versus radiation therapy alone in patients with stage III-B carcinoma of the cervix

Management of Late Complications of Pelvic Radiation in the Rectum and Anus

Contact Info

Product

Resources

About